Prostate Cancer Therapy

“When a patient first hears that they have a diagnosis of cancer, they usually aren’t ready to accept much more information at that point in time.” Why me? I exercised and had a good diet. Why? In this health video minute on prostate cancer, Drs. Tewari (leader in prostate cancer research and surgery) and Schlegel (Department Chairman) of Cornell Urology review the process of receiving and delivering a diagnosis of prostate cancer.

Duration : 0:1:23

Read the rest of this entry »

“I think the emotional preparedness is a key in the recovery after prostate cancer surgery.” Dr. Tewari, of the Dept. of Urology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, presents an insightful perspective on the emotional dimensions of prostate cancer and the critical role those emotions play in treatment and recovery.

Duration : 0:1:8

Read the rest of this entry »

“PSA allows us to detect prostate cancer several years before that nodule would develop, at a much earlier stage, and therefore at a much more curable stage.” Drs. Schlegel (Department Chairman) and Tewari of Cornell Urology discuss the application of PSA tests, digital rectum exams, and other approaches that enable urologists to diagnose prostate cancer earlier. A family history of prostate cancer and the implications relative to a diagnosis of prostate cancer is also discussed. The need to receive a PDA and at what age is also covered by one of the leading prostate cancer researchers.

Duration : 0:1:25

Read the rest of this entry »

“There’s no doubt that if the cancer is picked up early, it gives many more treatment options than if it’s picked up later.” Dr. Tewari (leader in prostate cancer research and surgery) of Cornell Urology discusses the critical importance of early detection in prostate cancer and the benefits it has for prostate cancer patients.

Duration : 0:0:57

Read the rest of this entry »

“The most important thing to prevent prostate cancer is to pick your parents properly.” Dr. Schlegel (Department Chairman) of Cornell Urology discusses a question they face often—Can prostate cancer be prevented? They discuss the role of race, diet, genetic profile and review important steps we can take to decrease our risk of facing prostate cancer.

Duration : 0:1:4

Read the rest of this entry »

New Prostate Cancer Procedure Being Tested in US Clinical Trials International HIFU

High Intensity Focused Ultrasound (HIFU) Procedure Reduces Side Effects, May Increase Quality of Life
January 2009 According to the American Cancer ociation, prostate cancer affects one in six men in the U.S. and is the second leading cause of cancer deaths in men. When caught and treated early, survival rates can be more than 90 percent, making swift treatment key.

Existing treatments however, can be limited and affect quality of life due to significant side effects, including loss of muscle mass, depression, decreased mental acuity and impotence. Now a High Intensity Focused Ultrasound (HIFU) procedure, available in 33 countries outside the US including Europe, is being tested in US Phase III clinical trials. HIFU is a minimally invasive procedure that uses the Sonablate(r) 500 ultrasound device to destroy cancerous tissue with focused sound waves.

By focusing sound waves in a targeted area, HIFU can rapidly increase the temperature in the focal zone, causing tissue destruction. This procedure is radiation-free and doesn’t preclude any other treatment options.

For more and more information regarding the risks and benefits ociated with HIFU, go to www.InternationalHIFU.com.

NOTE: Sonablate(r) 500 is not approved for use in the U.S. It remains investigational in the U.S. and is being studied as a prostate cancer treatment in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate(r)500 for the treatment of prostate cancer. USHIFU is a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies. International HIFU is the entity through which USHIFU conducts its international business operations and makes the HIFU technologies available to US patients at centers outside the United States where such technologies are approved.

Duration : 0:0:56

Read the rest of this entry »

“It’s like poking into a pillow in which a couple of golf balls are hidden.” Dr. Tewari, of the Dept. of Urology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses the prostate cancer biopsy and its effectiveness. While it’s the best they have, it is not perfect.

Duration : 0:1:4

Read the rest of this entry »

New Prostate Cancer Procedure Being Tested in US Clinical Trials International HIFU

High Intensity Focused Ultrasound (HIFU) Procedure Reduces Side Effects, May Increase Quality of Life
January 2009 According to the American Cancer ociation, prostate cancer affects one in six men in the U.S. and is the second leading cause of cancer deaths in men. When caught and treated early, survival rates can be more than 90 percent, making swift treatment key.

Existing treatments however, can be limited and affect quality of life due to significant side effects, including loss of muscle mass, depression, decreased mental acuity and impotence. Now a High Intensity Focused Ultrasound (HIFU) procedure, available in 33 countries outside the US including Europe, is being tested in US Phase III clinical trials. HIFU is a minimally invasive procedure that uses the Sonablate(r) 500 ultrasound device to destroy cancerous tissue with focused sound waves.

By focusing sound waves in a targeted area, HIFU can rapidly increase the temperature in the focal zone, causing tissue destruction. This procedure is radiation-free and doesn’t preclude any other treatment options.

For more and more information regarding the risks and benefits ociated with HIFU, go to www.InternationalHIFU.com.

NOTE: Sonablate(r) 500 is not approved for use in the U.S. It remains investigational in the U.S. and is being studied as a prostate cancer treatment in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate(r)500 for the treatment of prostate cancer. USHIFU is a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies. International HIFU is the entity through which USHIFU conducts its international business operations and makes the HIFU technologies available to US patients at centers outside the United States where such technologies are approved.

Duration : 0:3:37

Read the rest of this entry »

“The outcomes from surgical treatment of prostate cancer are dependent on the patient’s age, on the extent of the tumor, and to some degree the experience and results that an individual surgeon gets.” Dr. Schlegel, of the Dept. of Urology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, explains common expectations for patients entering into prostate cancer surgery and what factors those expectations are founded upon.

Duration : 0:1:11

Read the rest of this entry »

New Prostate Cancer Procedure Being Tested in US Clinical Trials International HIFU

High Intensity Focused Ultrasound (HIFU) Procedure Reduces Side Effects, May Increase Quality of Life
January 2009 According to the American Cancer ociation, prostate cancer affects one in six men in the U.S. and is the second leading cause of cancer deaths in men. When caught and treated early, survival rates can be more than 90 percent, making swift treatment key.

Existing treatments however, can be limited and affect quality of life due to significant side effects, including loss of muscle mass, depression, decreased mental acuity and impotence. Now a High Intensity Focused Ultrasound (HIFU) procedure, available in 33 countries outside the US including Europe, is being tested in US Phase III clinical trials. HIFU is a minimally invasive procedure that uses the Sonablate(r) 500 ultrasound device to destroy cancerous tissue with focused sound waves.

By focusing sound waves in a targeted area, HIFU can rapidly increase the temperature in the focal zone, causing tissue destruction. This procedure is radiation-free and doesn’t preclude any other treatment options.

For more and more information regarding the risks and benefits ociated with HIFU, go to www.InternationalHIFU.com.

NOTE: Sonablate(r) 500 is not approved for use in the U.S. It remains investigational in the U.S. and is being studied as a prostate cancer treatment in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate(r)500 for the treatment of prostate cancer. USHIFU is a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies. International HIFU is the entity through which USHIFU conducts its international business operations and makes the HIFU technologies available to US patients at centers outside the United States where such technologies are approved.

Duration : 0:2:49

Read the rest of this entry »